Occupational exposures to metals as risk factors for Parkinson's disease

Neurology

Volumn 48, Issue 3, 1997, Pages 650-658

  Gorell, Jay M ^a   Johnson, C C ^b   Rybicki, B A ^b   Peterson, E L ^b   Kortsha, G X ^e   Brown, G G ^c   Richardson, R J ^d  

^a HENRY FORD HOSPITAL   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; IRON; LEAD; MANGANESE; MERCURY; METAL; ZINC;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INDUSTRIAL HYGIENE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; WORK ENVIRONMENT;

EID: 0030940439     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.3.650     Document Type: Article

References (73)

1. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993;12:195-208.
2. Gorell JM. Clinical features and treatment of Parkinson's disease. In: Altman HJ, Altman BN, eds. Alzheimer's and Parkinson's diseases - recent advances in research and clinical management. New York: Plenum Press. 1989:67-84.
3. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 1984;16:278-282.
4. Koller W, O'Hara R, Weiner W, et al. Relationship of aging to Parkinson's disease. Adv Neurol 1986;45:317-321.
5. Marttila RJ, Rinne UK. Clues from epidemiology of Parkinson's disease. Adv Neurol 1986;45:285-288.
6. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14:317-335.
7. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-1051.
8. Kurtzke JF, Goldberg ID. Parkinsonism death rates by race, sex and geography. Neurology 1988;38:1558-1561.
9. Lilienfeld DE, Sekkor D, Simpson S, et al. Parkinsonism death rates by race, sex and geography: a 1980's update. Neuroepidemiology 1990;9:243-247.
10. Kessler, H. Epidemiologic studies of Parkinson's disease: II Hospital based survey. Am J Epidemiol 1972;95:308-318.
11. Kessler, H. Epidemiologic studies of Parkinson's disease: III A community-based survey. Am J Epidemiol 1972;96:242-254.
12. Padisson RM, Griffith RP. Occurrence of Parkinson's disease in black patients at Charity Hospital in New Orleans. Neurology 1974;24:688.
13. Kurtzke JF, Murphy FM. The changing patterns of death rates in parkinsonism. Neurology 1990;40:42-49.
14. Lilienfeld DE, Chan E, Ehland J, et al. Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol 1990;47:731-734.
15. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 1985;35:841-845.
16. Rosati G, Granieri E, Pinna L, et al. The risk of Parkinson's disease in Mediterranean people. Neurology 1980;30;250-255.
17. Gudmundsson KR. A clinical survey of parkinsonism in Iceland. Acta Neurol Scand 1967;33:9.
18. Li SC, Schoenberg BS, Wang CC, et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 1985;42:655-657.
19. Mutch WJ, Dingwall-Fordyce I, Downie AW, et al. Parkinson's disease in a Scottish city. BMJ 1986;292:534.
20. Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. Arch Neurol 1983;40:151-154.
21. Svenson LW. Regional disparities in the annual prevalence rates of Parkinson's disease in Canada. Neuroepidemiology 1991;10:205-210.
22. Granieri E, Carreras M, Casetta I, et al. Parkinson's disease in Ferrara, Italy, 1967 through 1987. Arch Neurol 1991;48: 854-857.
23. Hofman A, Collette HJA, Bartelds AIM. Incidence and risk factors of Parkinson's disease in the Netherlands. Neuroepidemiology 1989;8:296-299.
24. Sutcliffe RLG, Prior R, Mawby B, McQuillan WJ. Parkinson's disease in the district of Northampton Health Authority, United Kingdom: a study of prevalence and disability. Acta Neurol Scand 1985;72:363-379.
25. Bharucha NE, Bharucha EP, Bharucha AE, et al. Prevalence of Parkinson's disease in the Parsi community of Bombay, India. Arch Neurol 1988;45:1321-1323.
26. Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970-1989. Neurology 1994;44:1865-1868.
27. Tanner CM, Chen B, Wang W, et al. Environmental factors and Parkinson's disease: a case-control study in China. Neurology 1989;39:660-664.
28. Zayed J, Ducic S, Campanella G, et al. Facteurs environnementaux dans l'étiologie de la maladie de Parkinson. Can J Neurol Sci 1990;17:286-291.
29. Jimenez-Jimenez FJ, Gonzales DM, Gimenez-Roldan S. Exposure to well water drinking and pesticides in Parkinson's disease: a case-control study from the southeast area of Madrid [abstract]. Proceedings of the 9th Intl Symposium on Parkinson's disease. World Federation of Neurology 1988:118.
30. Aquilonius SM, Hartvig P. A Swedish country with unexpectedly high utilization of anti-parkinsonian drugs. Acta Neurol Scand 1986;74:379-382.
31. Hertzman C, Wiens M, Bowering D, et al. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am J Ind Med 1990;17:349-355.
32. Wang W, Fang X, Cheng X, et al. A case-control study on the environmental risk factors of Parkinson's Disease in Tianjiu, China. Neuroepidemiology 1993;12:209-218.
33. Rybicki BA, Johnson CC, Uman JE, Gorell JM. Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov Disord 1993;8:87-92.
34. Jimenez-Jimenez FJ, Mateo D, Gimenez RS. Exposure to well water and pesticides in Parkinson's disease: a case-control study in the Madrid area. Mov Disord 1992;7:149-152.
35. Seidler A, Hellenbrand W, Robra BP, et al. Possible environtal and occupational and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996;46:1275-1284.
36. Weschler LS, Checkoway H, Franklin GM, Costa LG. A pilot study of occupational and environmental risk factors for Parkinson's disease. Neurotoxicology 1991;12:387-392.
37. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43: 1173-1180.
38. Ngim CH, Devathasan G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. Neuroepidemiology 1989;8:128-141.
39. Ohlson CG, Hogstedt C. Parkinson's disease and occupational exposure to organic solvents, agricultural chemicals and mercury: a case-referent study. Scand J Work Environ Health 1981;7:252-256.
40. Mutch WJ, Smith WC, Scott RF. A screening and alerting questionnaire for parkinsonism. Neuroepidemiology 1991;10: 150-156.
41. Folstein M, Folstein S, McHugh PR. Mini-mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
42. Anthony JC, LeResche LR, VonKorff MR, et al. Limits of the "Mini-mental state" as a screening test for dementia and delirium among hospital patients. Psychol Med 1982;12:397.
43. Rybicki BA, Johnson CC, Gorell JM. Demographic differences in referral rates to neurologists of patients with suspected Parkinson's disease: implications for case-control study design. Neuroepidemiology 1995;14:72-81.
44. Mena I, Marin O, Fuenzalida S, Cotzias GC. Chronic manganese poisoning - clinical picture and manganese turnover. Neurology 1967;17:128-136.
45. Huang C-C, Chu N-S, Lu C-S, et al. Chronic manganese intoxication. Arch Neurol 1989;46:1104-1106.
46. Huang C-C, Lu C-S, Chu N-S, et al. Progression after chronic manganese exposure. Neurology 1993;43:1479-1483.
47. Doig AT, McLaughlin AIG. X-ray appearances of lungs of electric arc welders. Lancet 1936;1:771-775.
48. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
49. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-807.
50. -. J Free Radic Biol Med 1986;2:3-11.
51. Kawanishi S. Role of active oxygen species in metal-induced DNA damage. In: Goyer RA, Cherian MG, eds. Handbook of experimental pharmacology. Vol 115. Toxicology of metals -biochemical aspects. Berlin: Springer-Verlag, 1995:349-371.
52. Sofic E, Paulus W, Jellinger K, et al. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-982.
53. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
54. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
55. Archibald FS, Tyree C. Manganese poisoning and the attack of trivalent manganese upon catecholamines. Arch Biochem Biophys 1987;256:638-650.
56. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-643.
57. Montine TJ, Farris DB, Graham DG. Covalent crosslinking of neurofilament proteins by oxidized catechols as a potential mechanism of Lewy body formation. J Neuropathol Exp Neurol 1995;54:311-319.
58. Gibb WRG, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989;15:27-44.
59. Stich HF, Wei L, Whiting RF. Enhancement of the chromosome-damaging action of some reducing agents. Cancer Res 1979;39:4145-4151.
60. Spencer JP, Jenner A, Aruoma GI, et al. Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett 1994;353: 246-250.
61. Schapira AHV. Evidence for mitochondrial dysfunction in Parkinson's disease - a critical reappraisal. Mov Disord 1994;9: 125-138.
62. Richter C, Park JW, Ames BX. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988;85:6465-6467.
63. Singh G, Sharkey SM, Moorehead R. Mitochondrial DNA damage by anticancer agents. Pharmacol Ther 1992;54:217-230.
64. Itoh H, Shioda T, Matsura T, et al. Iron ion induces mitochondrial DNA damage in HTC rat hepatoma cell culture: role of antioxidants in mitochondrial DNA protection from oxidative stresses. Arch Biochem Biophys 1994;313:120-125.
65. Tritschler HJ, Medori R. Mitochondrial DNA alterations as a source of human disorders. Neurology 1993;43:280-288.
66. Tritschler HJ, Packer L, Medori R. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Biochem Mol Biol Int 1994;34:169-181.
67. Rossman TG. Metal mutagenesis. In: Goyer RA, Cherian MG, eds. Handbook of experimental pharmacology. Vol. 115. Toxicology of metals - biochemical aspects. Berlin: Springer-Verlag, 1995:373-405.
68. Popenoe EA, Schmaeler MA. Interaction of human DXA polymerase β with ions of copper, lead and cadmium. Arch Biochem Biophys 1979;106:190-201.
69. Rao KS. Genomic damage and its repair in young and aging brain. Mol Neurobiol 1993;7:23-48.
70. Evans DA, Burbach JP, van Leeuwen FW. Somatic mutations in the brain: relationship to aging? Mutat Res 1995;338:173-182.
71. Coughlin SS, Chiazze L. Job-exposure matrices in epidemiologic research and medical surveillance. Occup Med 1990;5: 633-646.
72. Stengel B, Pisani P, Limasset JC, Bouyer J, Berrino F, Hemon D. Retrospective evaluation of occupational exposure to organic solvents: questionnaire and job exposure matrix. Int J Epidemiol 1993;22(Suppl 2):S72-S82.
73. Stucker I, Bouyer J, Mandereau L, Hemon D. Retrospective evaluation of the exposure to polycyclic aromatic hydrocarbons: comparative assessments with a job exposure matrix and by experts in industrial hygiene. Int J Epidemiol 1993; 22(Suppl 2):S106-S112.